全文获取类型
收费全文 | 538篇 |
免费 | 43篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 19篇 |
妇产科学 | 15篇 |
基础医学 | 81篇 |
口腔科学 | 4篇 |
临床医学 | 50篇 |
内科学 | 90篇 |
皮肤病学 | 3篇 |
神经病学 | 86篇 |
特种医学 | 5篇 |
外科学 | 45篇 |
综合类 | 2篇 |
预防医学 | 61篇 |
眼科学 | 11篇 |
药学 | 47篇 |
中国医学 | 5篇 |
肿瘤学 | 54篇 |
出版年
2024年 | 5篇 |
2023年 | 20篇 |
2022年 | 17篇 |
2021年 | 29篇 |
2020年 | 35篇 |
2019年 | 36篇 |
2018年 | 29篇 |
2017年 | 20篇 |
2016年 | 27篇 |
2015年 | 26篇 |
2014年 | 18篇 |
2013年 | 34篇 |
2012年 | 46篇 |
2011年 | 44篇 |
2010年 | 22篇 |
2009年 | 14篇 |
2008年 | 32篇 |
2007年 | 26篇 |
2006年 | 12篇 |
2005年 | 16篇 |
2004年 | 18篇 |
2003年 | 9篇 |
2002年 | 10篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 3篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1982年 | 2篇 |
1980年 | 2篇 |
1978年 | 1篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1966年 | 1篇 |
1965年 | 1篇 |
1961年 | 1篇 |
1951年 | 1篇 |
1950年 | 1篇 |
1924年 | 1篇 |
1923年 | 1篇 |
排序方式: 共有581条查询结果,搜索用时 187 毫秒
571.
572.
573.
Dennis Zetner Claus Kamby Sengül Gülen Camilla Christophersen Cecilie B. Paulsen Emily Piga Bodil Hoffmeyer Faisal Mahmood Jacob Rosenberg 《Journal of pineal research》2023,74(1):e12840
The aim of this double-blind, placebo-controlled, randomized study was to investigate whether topical melatonin administered during radiation therapy could increase the quality of life in patients with primary breast cancer. Patients were followed from the first radiation fraction until 3 weeks after the last. The patients applied 1 g of cream to the irradiated area of the skin twice daily, consisting of either 25 mg/g melatonin and 150 mg/g dimethyl sulfoxide, or a placebo cream. Outcomes were the European Organisation for Research and Treatment of Cancer's quality-of-life questionnaires for breast cancer (QLQ-C30 and QLQ-BR23) on the last day of radiation therapy. As a secondary outcome, we evaluated the breast symptom (BS) scores over the entire duration of the trial in a repeated measures linear model. We included 65 patients and had 17 drop-outs, thus totaling 26 and 22 patients in the melatonin and placebo groups, respectively. BS scores on the last day of radiation did not differ between groups (p = .333). However, the linear model analyzing BS for the entire duration showed that melatonin significantly decreased the symptoms (p = .001). There was no difference in the BS score on the last day of radiation, however, we found that the patients in the melatonin group had significantly lower BS scores over the entire duration of the trial. 相似文献
574.
Maria Skaalum Petersen Laura Pérez-Alós Jose Juan A. Armenteros Cecilie B. Hansen Jógvan Páll Fjallsbak Sólrun Larsen Jóhanna L. Hansen Ida Jarlhelt Marnar F. Kristiansen Fríða við Streym Bjarni á Steig Debes H. Christiansen Lars F. Møller Marin Strøm Guðrið Andorsdóttir Shahin Gaini Pál Weihe Peter Garred 《Journal of internal medicine》2023,293(1):63-81
575.
Belinda J. Lawford Hiral Master Jesper B. Larsen Cecilie Bartholdy Patrick Corrigan Elisabeth Ginnerup-Nielsen Christina Le Anthony Teoli Kim L. Bennell Ben Metcalf Rana S. Hinman Kate Button Natalie J. Collins Elizabeth Cottrell Yves Henrotin Søren T. Skou Louise M. Thoma Elizabeth Wellsandt Daniel K. White Melanie A. Holden 《Musculoskeletal care》2023,21(2):545-555
576.
Tina Okdahl Esben Bolvig Mark Rasmus Bach Nedergaard Cecilie Siggaard Knoph Mathias Ellgaard Cook Klaus Krogh Asbjørn Mohr Drewes 《Basic & clinical pharmacology & toxicology》2023,132(5):434-448
Opioids change gut motility, and opium tincture has been used for treatment of chronic diarrhoea for centuries. However, the effects have never been documented in controlled trials. We aimed to investigate the effects of opium tincture on gastrointestinal transit and motility, frequency of bowel movements, stool consistency, gastrointestinal symptoms and sedation. Twenty healthy subjects were included in this randomized controlled trial. Opium tincture or placebo was each applied for 9 days. Gastrointestinal transit and motility were investigated with the 3D-transit system. Bowel movements and gastrointestinal symptoms were recorded daily. General cognition, reaction time, memory and electroencephalography were used to assess effects on the central nervous system. Opium tincture doubled colonic transit (49 vs. 23 h, p < 0.001), decreased antegrade colonic movements (p < 0.05), reduced daily bowel movements (0.7 vs. 1.2, p < 0.001) and increased stool consistency (Type 3 vs. Type 4, p < 0.001). No changes in general cognition, reaction time or memory were observed, and minor changes of power observed by electroencephalography did not indicate sedation. This study is the first to show that opium tincture has anti-propulsive properties in the healthy gut, while no sedative effects were seen. This indicates that opium tincture is a relevant and safe treatment option in chronic diarrhoea. 相似文献
577.
Kjell Inge Erikstad Ida Herdlevær Elise Peter Mette Haugen Cecilie Totland Christian Vedeler 《European journal of neurology》2023,30(6):1727-1733
Background and purpose
Commercially available tests for Yo antibody detection have low specificity for paraneoplastic cerebellar degeneration (PCD) because these assays use cerebellar degeneration-related protein 2 (CDR2) as the antigen, not CDR2-like (CDR2L). We aimed to test the hypothesis that use of a CDR2L cell-based assay (CBA), as an additional screening technique, would increase the accuracy of Yo-PCD diagnosis.Methods
An in-house CBA to test for anti-CDR2L antibodies was developed and used to screen sera from 48 patients with confirmed anti-Yo-associated PCD. Fifteen non-Yo PCD patients, 22 patients with ovarian cancer without neurological syndromes, 50 healthy blood donors, 10 multiple sclerosis, 15 Parkinson's disease, and five non-paraneoplastic ataxic patients were included as controls. Sera were also tested by western blot analysis using recombinant CDR2 and CDR2L proteins developed in house, by the commercially available line immunoassays from Ravo Diagnostika and Euroimmun, and by the CDR2 CBA from Euroimmun.Results
The CDR2L CBA identified all 48 patients with Yo-PCD. No CDR2L CBA reaction was observed in any of the control sera. The western blot technique had lower sensitivity and specificity as sera from eight and six of the 48 Yo-PCD patients did not react with recombinant CDR2 or CDR2L, respectively.Conclusions
The CDR2L CBA is highly reliable for identification of Yo-PCD. Although our findings indicate that, currently, the combination of CDR2 and CDR2L yields the most reliable test results, it remains to be evaluated if a test for single anti-CDR2L positivity will serve as a sufficient biomarker for Yo-PCD diagnosis. 相似文献578.
Christian R. Juhl MD Josephine Burgdorf MSc Cecilie Knudsen MD Anniek F. Lubberding PhD Simon Veedfald MD Jonas L. Isaksen MSc Bolette Hartmann PhD Ruth Frikke-Schmidt MD Thomas Mandrup-Poulsen MD Jens J. Holst MD Jørgen K. Kanters MD Signe S. Torekov PhD 《Diabetes, obesity & metabolism》2023,25(1):98-109
579.
580.
Cecilie Johannessen Landmark Sara Eyal Margrete Larsen Burns Valentina Franco Svein I. Johannessen 《Epileptic Disord》2023,25(4):454-471
Antiseizure medications (ASMs) are the cornerstone of treatment for patients with epilepsy. Several new ASMs have recently been introduced to the market, making it possible to better tailor the treatment of epilepsy, as well as other indications (psychiatry and pain disorders). For this group of drugs there are numerous pharmacological challenges, and updated knowledge on their pharmacodynamic and pharmacokinetic properties is, therefore, crucial for an optimal treatment outcome. This review focuses on educational approaches to the following learning outcomes as described by the International League Against Epilepsy (ILAE): To demonstrate knowledge of pharmacokinetics and pharmacodynamics, drug interactions with ASMs and with concomitant medications, and appropriate monitoring of ASM serum levels (therapeutic drug monitoring, TDM). Basic principles in pharmacology, pharmacokinetic variability, and clinically relevant approaches to manage drug interactions are discussed. Furthermore, recent improvements in analytical technology and sampling are described. Future directions point to the combined implementation of TDM with genetic panels for proper diagnosis, pharmacogenetic tests where relevant, and the use of biochemical markers that will all contribute to personalized treatment. These approaches are clinically relevant for an optimal treatment outcome with ASMs in various patient groups. 相似文献